Targeting Hypoxia in Leukemia Treatment with PR-104
Author Information
Author(s): Benito Juliana, Shi Yuexi, Szymanska Barbara, Carol Hernan, Boehm Ingrid, Lu Hongbo, Konoplev Sergej, Fang Wendy, Zweidler-McKay Patrick A., Campana Dario, Borthakur Gautam, Bueso-Ramos Carlos, Shpall Elizabeth, Thomas Deborah A., Jordan Craig T., Kantarjian Hagop, Wilson William R., Lock Richard, Andreeff Michael, Konopleva Marina
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
Does hypoxia in the bone marrow microenvironment contribute to chemoresistance in leukemia?
Conclusion
Targeting hypoxia in the leukemic bone marrow using the prodrug PR-104 may significantly improve leukemia therapy.
Supporting Evidence
- Hypoxia was found to promote chemoresistance in various ALL-derived cell lines.
- PR-104 significantly decreased leukemia burden in immune-deficient mice injected with primary ALL cells.
- HIF-1α was expressed at high levels in bone marrow biopsies from ALL patients at diagnosis.
Takeaway
This study found that leukemia cells thrive in low-oxygen areas of the bone marrow, making them harder to kill with standard treatments. A new drug, PR-104, can help target these tough cells.
Methodology
The study used xenograft models and in vitro experiments to assess the effects of hypoxia on leukemia cells and the efficacy of PR-104.
Potential Biases
Potential bias in the selection of models and the interpretation of results.
Limitations
The study primarily focused on murine models and may not fully translate to human patients.
Participant Demographics
The study included bone marrow samples from 9 pediatric ALL patients at diagnosis and after treatment.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website